Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 19;9:199–206. doi: 10.2147/DDDT.S75495

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Ba et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Effects of pretreatment with PSD-95 ASO or MSO on the augmented tyrosine phosphorylation of NR2B induced by chronic L-dopa treatment in lesioned rat striatum.

Notes: Samples were from the group of control, PD, and chronic L-dopa treatment rats and L-dopa treatment + PSD-95 ASO or PSD-95 MSO (n=5). (A) Tyrosine phosphorylation of NR2B examined by IP with anti-NR2B antibody followed by IB with anti-pY. (B) IB analysis of the protein levels of NR2B with anti-NR2B antibody. (C) Quantitative representation of NR2B tyrosine phosphorylation (p-NR2B) and the protein levels of NR2B. ^#P<0.05 versus PD; ^&P<0.05 versus chronic L-dopa (day 22) group; ^$P<0.05 versus PSD-95 ASO group. The results were repeatable on striatal extracts from five rats.

Abbreviations: anti-pY, antibody against phosphotyrosine; IB, immunoblotting; IP, immunoprecipitation; L-dopa, levodopa; PD, Parkinson’s disease; PSD-95 ASO, PSD-95mRNA antisense oligonucleotides; PSD-95 MSO, PSD-95mRNA scrambled missense oligonucleotides.